Ionis Pharmaceuticals, Inc.’s Post

Check out this recent journal article from TMS Medical Advisory Board member Dr. Joseph Butterfield (and Dr. Kathleen Bartemes); "Metformin: A potential adjunct for treatment of systemic mastocytosis." This is an open-access article published last month and will be included in the February 2024 issue of the Journal of Allergy and Clinical Immunology Global. We think the preliminary findings in this article are pretty exciting. https://buff.ly/3S0X9s5

🗞️ Top Stories of 2023 from the CU School of Medicine 🗞️ Story #1: Brent Palmer, PhD, associate professor of allergy and clinical immunology, hypothesizes that "long COVID" is caused by hidden viral reservoirs that remain in the body after the initial infection. Read this story here: https://bit.ly/41jSXGT See the other top stories here: https://bit.ly/4aeDZFY #COVID19 #Pandemic

ICYMI: We presented new Phase 3 data for our investigational medicine for the treatment of hereditary angioedema (#HAE) during a late-breaking session at the 2024 European Academy of Allergy and Clinical Immunology - EAACI Congress, which was simultaneously published in The New England Journal of Medicine. HAE is a rare and life-threatening genetic condition that involves recurrent attacks of severe swelling in various parts of the body, which can cause severe pain and significantly disrupt daily life.    We’re committed to advancing research to better understand how to improve the lives of people living with this #RareDisease, which affects about 20,000 people across the U.S. and Europe. #EAACIcongress 

Cutaneous involvement in patients with Systemic Lupus Erythematosus: let’s talk about it! Three days full of lectures here in Turin, Italy, for the annual congress of allergy and clinical immunology.

🔬 Exclusive EAACI Webinar Now Streaming! 🌟“Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs“.🌟 Join us on a comprehensive exploration of the EAACI position paper, a landmark document in the field of allergy and clinical immunology. This webinar is an opportunity to delve into a significant step forward in understanding and managing allergic diseases and hypersensitivity reactions. #EAACIWebinar #Nomenclature #Allergicdiseases Learn how this paper impacts current and future diagnostic and therapeutic approaches, with a focus on precision medicine and individualized patient care. The session features a special talk by Marek Jutel and Ioana Agache, the paper's first authors, offer their unique perspectives and insights. 🔗 Access it now on the EAACI Knowledge Hub: https://ow.ly/SWuT50QeIP2 Hypersensitivity reactions originally described by Gell and Coombs have been extended into nine different types comprising antibody- (I-III), cell-mediated (IVa-c), tissue-driven mechanisms (V-VI) and direct response to chemicals (VII). Types I-III are linked to classical and newly described clinical conditions. Type IVa-c are specified and detailed according to the current understanding of T1, T2 and T3 responses. Types V-VI involve epithelial barrier defects and metabolic-induced immune dysregulation, while direct cellular and inflammatory responses to chemicals are covered in type VII.

As always, I'm always so excited with each new academic year to see the new fellows bring their ideas and passions to our program. The beautiful thing with the academic cycle is the yearly "refresh" button: New fellows come and invigorate the program, current fellows become seniors and peer mentors, graduating fellows go on to new positions where they leverage their strengths and expand into new leadership roles to mentor the next generation of trainees. #MedEd #AIMedEd #Allergy #Immunology

High-Throughput Cell-Line Development U.S. government researchers have made a significant step forward in developing a fully automated process for cell-line development. The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, hopes the new improvements are a move towards reducing cell-line development timescales to help tackle future pandemics. https://hubs.ly/Q02KHlhX0

Cell line development can be a bottleneck in drug discovery because it can be challenging and time consuming. High-throughput cell line development is an impressive achievement speeding up the drug discovery processes. 

High-Throughput Cell-Line Development U.S. government researchers have made a significant step forward in developing a fully automated process for cell-line development. The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, hopes the new improvements are a move towards reducing cell-line development timescales to help tackle future pandemics. https://hubs.ly/Q02Km1qj0